Thursday, April 10, 2014
I already believe Mannkind is overvalued due to it's $2.5 billion market cap, weak balance sheet, and lack of commercial partner. Now they have another possible inhaled insulin competitor with a planned phase 3 trial next year. Take a look at Adam's article for the details.
Tuesday, April 8, 2014
As expected, Sunesis (SNSS) reported positive preliminary results of it's lead compound, Vosaroxin, in a phase 1b/2 study in AML and MDS. The drug, combined with decitabine, had an overall response rate of 67% in the 24 patients treated. Webush commented on the results and reiterated it's $10 price target on Sunesis.
Monday, April 7, 2014
The American Association of Cancer Research 105th annual meeting is underway which sometimes provides opportunities for short term trades ahead of press releases for data presentations. I think Sunesis (SNSS) is such an opportunity as updated phase 1b/2 data on it's lead compound, Vosaroxsin, in AML and MDS will be presented tomorrow. I pulled the abstract and it's showing an 67% response rate which is a solid result and I'd expect a press release tomorrow to communicate these results. I purchased 5,000 shares ahead of the data presentation.